Hand Eczema – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Hand Eczema Market Outlook

Thelansis’s “Hand Eczema Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hand Eczema treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hand Eczema Overview

Hand eczema, or dermatitis, is frequently a persistent and complex condition. Its primary indications encompass dry, itchy skin that appears red or darker than the surrounding skin. Additional symptoms encompass skin fissures, soreness, and bleeding, with the potential development of blisters in certain instances. Typically, the skin becomes dry, scaly, and thickened, and during flare-ups, the fingers can become swollen, causing considerable discomfort. Hand eczema can hinder daily activities like buttoning clothes, writing, or using a computer in severe, long-lasting cases. Most hand eczema cases have multiple causative factors, broadly categorized as exogenous or endogenous. Among exogenous triggers, contact irritants, such as soaps, detergents, rubber, and various substances like vegetables, are often attributed to hand eczema. Physical friction and minor injuries can also lead to irritant contact dermatitis. Additionally, ingested allergens like nickel chromium and topically applied medications like neomycin and hydroxyquinolones can contribute to hand eczema. Dermatophytide reactions associated with tinea pedis can also affect the hands. Certain professions, including hairdressers, farmers, construction workers, dental and medical personnel, metalworkers, and food handlers, are prone to developing hand eczema. Various clinical patterns of hand eczema exist, primarily differing in clinical presentation rather than histology. These patterns include hyperkeratotic (resembling psoriasis or tylotic eczema), frictional, nummular, atopic, pompholyx (also known as dyshidrosis), and chronic vesicular hand dermatitis. Hybrid variations of these patterns are also observed, and there is some disagreement among experts regarding their classification. Clinically, hand eczema is characterized by observable signs such as redness, vesicles, papules, scaling, fissures, hyperkeratosis, and bothersome symptoms like itching and pain. "chronic hand eczema" applies when the condition persists for over six months. While diagnosing hand eczema may seem straightforward, it can occasionally be challenging to distinguish it from other dermatological conditions such as psoriasis, tinea mannum, lichen planus, pityriasis rubra pilaris, and palmar pustulosis. Treatment for hand eczema traditionally involves topical corticosteroids, oral antihistamines, emollients, and, in severe cases, short courses of systemic corticosteroids based on the disease's severity. Topical steroids are typically the first-line treatment for managing inflammation, with various types like desonide, mometasone furoate, clobetasol propionate, and betamethasone dipropionate, among others, being employed in hand eczema therapy.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: